KR20190012650A - Composition for Preventing or Treating Olmesartan-Induced Tachycardia Comprising Linalyl Acetate - Google Patents

Abstract

The present invention relates to a composition for preventing or treating tachycardia induced by olmesartan containing linalyl acetate. More specifically, the present invention relates to a pharmaceutical composition containing linalyl acetate as an active component which can be usefully used for preventing or treating increased heart rate which is a side effect of olmesartan. The composition containing linalyl acetate according to the present invention has an excellent effect of preventing or normalizing tachycardia induced by olmesartan. Therefore, the composition can be useful for developing a medicine or a health functional food for preventing, alleviating or treating increased heart rate, which is the side effect of an antihypertensive agent, olmesartan.

Description

TECHNICAL FIELD [0001] The present invention relates to a composition for preventing or treating tachycardia induced by olmesartan including linaryl acetate,

The present invention relates to a composition for preventing or treating tachycardia caused by olmesartan comprising linalyl acetate and more particularly to a composition for prevention or treatment of increase in heart rate which is a side effect of olmesartan The present invention also relates to a pharmaceutical composition comprising linaryl acetate as an effective ingredient.

Hypertension generally refers to when the systolic blood pressure is 140 mmHg and the diastolic blood pressure is 90 mmHg or more. Prolonged hypertension is associated with cardiovascular diseases, such as stroke, coronary artery disease, peripheral vascular disease, and congestive heart failure, as well as complications such as chronic renal disease and hypertensive retinopathy. The number of deaths due to cardiovascular disease worldwide is estimated to reach more than 17.3 million people per year in 2013 (Roth et al., N Engl J Med . 372: 1333-1341, 2015) Because hypertension is reported in third place with 9.0% (Mozaffarian et al., Circulation. 133 (4): e38-360, 2016), thorough blood pressure control is considered important. The nonpharmacologic treatment of hypertension is diet, exercise, and weight control. When the nonpharmacologic treatment does not improve, medication is started. Currently, various oral therapeutic agents for controlling blood pressure have been developed. Typical examples include diuretics, beta blockers, calcium channel antagonists, angiotensin converting enzyme inhibitors, angiotensin II receptor blockers, and alpha blockers.

Angiotensin II receptor blockers are antagonists of angiotensin II receptors and block angiotensin II hypertensive effects and play important roles in blood pressure, water, and electrolyte control. Several studies have shown that olmesartan (OM) is more effective than captopril, losartan, valsartan, and irbesartan in lowering systolic or diastolic blood pressure Although its effect has been confirmed (Norwood et al., Drug forecast. 27 (12): 611-618, 2002). According to olmesartan (OM) drug information, dizziness, headache, diarrhea, and hyperglycemia are reported as side effects of 1 ~ 10%. Tachycardia is an uncommon side effect with an incidence of 0.1 to 1%, but it causes discomfort and anxiety due to palpitations. Excessive heart rate increases blood pressure and may cause dizziness. It is necessary to develop an antihypertensive agent including a natural product preparation which can be reduced.

Linalyl acetate (LA) contains many essential oils, especially Bergamot (Citrus bergamia Risso), Clary sage (Salvia sclarea), Neroli (Citrus aurantium L. var. Amara), Lavender , Lavandula angustifolia), a colorless, aromatic fragrance which has been proven in various studies on cells, animals and the human body. Linaryl acetate reduced melanin production by melanocyte-stimulating hormone by inhibiting the activity of tyrosinase in melanoma cells (Peng et al., PLoS ONE. 9 (4): e95186, 2014) 9 (8): 721-726 (1995)) . In the present study, it was shown that the anti-inflammatory effect was suppressed by reducing the volume of swelling when carrageenin was injected into the hind paw after the injection of linaryl acetate (Peana et al., Phytomedicine. , 2002), and inhalation of linaryl acetate significantly reduced pain intensity and residual sensation in patients who removed urinary catheterization after colorectal cancer surgery (So Hyun Yu and Geun Hee Seol, Evidence-Based Complementary and Alternative Medicine. , ≪ / RTI > Article ID 3954181, 2017). In rats exposed to nicotine in an acute manner, linaryl acetate showed that linaryl acetate may have a positive effect on autonomic balance by restoring normal heart rate reduction to nicotine exposure (Kim et al. Environmental Health and Preventive Medicine. 22 (1): 42-48, 2017), the adverse effects of antihypertensive agents have not yet been linked to the prevention or treatment of abnormally increased heart rate.

The present inventors have tried to overcome limitations of conventional antihypertensive medicines and to develop new agents capable of reducing side effects, and as a result, it has been found that linaryl acetate exerts excellent effects of suppressing heart rate increase phenomenon and tachycardia which are side effects of olmesartan And completed the present invention.

It is an object of the present invention to provide a pharmaceutical composition and a health functional food for relieving or inhibiting side effects caused by olmesartan (OM) containing linalyl acetate (LA) as an active ingredient.

In order to achieve the above object, the present invention provides a pharmaceutical composition for alleviating or inhibiting side effects caused by olmesartan containing linalyl acetate as an active ingredient.

The present invention also provides a pharmaceutical composition for preventing or treating heart rate increase or tachycardia comprising linaryl acetate as an active ingredient.

The present invention also provides a health functional food for alleviating or inhibiting side effects caused by olmesartan containing linaryl acetate as an active ingredient.

The present invention also provides a health functional food for preventing or ameliorating heart rate increase or tachycardia comprising linaryl acetate as an active ingredient.

The composition comprising linalyl acetate according to the present invention is excellent in preventing or alleviating tachycardia induced by olmesartan, and thus is useful as an antihypertensive agent for the prevention and alleviation of increase in heart rate, Or for the development of medicines or health functional foods for treatment.

FIG. 1 is a graph comparing heart rates between a normal blood pressure group and a hypertensive group after completion of a rat hypertension model. (Normotension: normal blood pressure group, hypertension: hypertension group)
FIG. 2 is a graph comparing heart rates according to olmesartan (OM) administration or linalyl acetate (LA) injection in the hypertensive group. (Vehicle: hypertension control group, OM: olmesartan 10 mg / kg group, LA10: linaryl acetate 10 mg / kg injected group, LA100: linaryl acetate 100 mg / kg injected group, OM + LA10: olmesartan 10 mg / 10 mg / kg of reel acetate, OM + LA100: 10 mg / kg of olmesartan and 100 mg / kg of linaryl acetate)

Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs. In general, the nomenclature used herein is well known and commonly used in the art.

In the present invention, after completing a hypertensive rat model, the increase in heart rate caused by olmesartan, an antihypertensive agent, was confirmed, and linalyl acetate was effective in alleviating the increase in heart rate or tachycardia, which is a side effect of olmesartan It is confirmed that it is excellent.

Therefore, in one aspect, the present invention relates to a pharmaceutical composition for alleviating or inhibiting side effects caused by olmesartan containing linaryl acetate as an active ingredient.

In the present invention, the adverse effect caused by olmesartan may be a heart rate increase or tachycardia.

In another aspect, the present invention relates to a pharmaceutical composition for preventing or treating heart rate increase or tachycardia comprising linaryl acetate as an active ingredient.

As used herein, the term " side effect " means the drug efficacy, or narrowly, the drug adverse reaction that appears in addition to the main action of the drug.

As used herein, the term " prevention " means inhibiting or delaying the increase in heart rate, which is an adverse side effect of olmesartan, by administration of the pharmaceutical composition according to the present invention.

As used herein, the term " treatment " is meant to include any action that improves or alters the increase in heart rate, an adverse side effect of olmesartan, by administration of a pharmaceutical composition according to the present invention.

As used herein, "heart rate" refers to the number of times the heart is beating for one minute and is usually equal to the pulse rate.

In one embodiment of the present invention, in order to evaluate the effect of linaryl acetate on heart rate increase, which is an adverse effect of olmesartan, an antihypertensive agent, 10 mg / kg oral olmesartan or linaryl acetate 10 mg / kg daily for 1 week in hypertension control , 100 mg / kg, and the heart rate was measured. As a result, it was confirmed that heart rate was significantly decreased when linaryl acetate was administered.

Therefore, in view of the above results, the composition comprising linaryl acetate as an active ingredient according to the present invention is useful as a medicament useful for preventing or treating heart rate increase, which is a side effect of olmesartan, and a health functional food composition for prevention or improvement .

The pharmaceutical composition of the present invention may further comprise a pharmaceutically acceptable carrier, excipient or diluent. A " pharmaceutically acceptable carrier " is a substance that can be added to the active ingredient to help formulate or stabilize the formulation and does not cause significant toxic effects on the patient.

The carrier refers to a carrier or diluent that does not irritate the patient and does not interfere with the biological activity and properties of the linaryl acetate according to the present invention. Examples of the pharmaceutical carrier that is acceptable for the composition to be formulated into a liquid solution include sterilized and sterile water, sterile water, Ringer's solution, buffered saline, albumin injection solution, dextrose solution, maltodextrin solution, glycerol, One or more of these components may be mixed and used. If necessary, other conventional additives such as an antioxidant, a buffer, and a bacteriostatic agent may be added. In addition, diluents, dispersants, surfactants, binders, and lubricants can be additionally added and formulated into injectable solutions, pills, capsules, granules or tablets such as aqueous solutions, suspensions, emulsions and the like. Other carriers are described, for example, in Remington ' s Pharmaceutical Sciences (E. W. Martin).

Pharmaceutically acceptable carriers include sterile aqueous solutions or dispersions and sterile powders for the extemporaneous preparation of sterile injectable solutions or dispersions. The use of such media and agents for pharmaceutical active materials is well known in the art. The composition is preferably formulated for parenteral use. The compositions may be formulated as solutions, microemulsions, liposomes, or other ordered structures suitable for high drug concentrations. The carrier can be, for example, a solvent or dispersion medium containing water, ethanol, a polyol (such as glycerol, propylene glycol and liquid polyethylene glycol, etc.) and suitable mixtures thereof. In some cases, the composition may include isotonic agents, for example, sugars, polyalcohols such as mannitol, sorbitol or sodium chloride. Sterile injectable solutions may be prepared by incorporating the requisite amount of linaryl acetate into a suitable solvent, optionally together with one or a combination of the ingredients described above followed by sterile microfiltration. In general, dispersions are prepared by incorporating the active compound into a sterile vehicle containing a basic dispersion medium and other necessary ingredients from those described above. In the case of sterile powders for the preparation of sterile injectable solutions, some preparative methods involve vacuum drying and freeze-drying (freeze-drying), which produces powders of the active ingredient and any additional desired ingredients from a pre-sterilized- )to be.

In the case of formulation, a diluent or excipient such as a filler, an extender, a binder, a wetting agent, a disintegrant, or a surfactant is usually used. Solid formulations for oral administration include tablets, pills, powders, granules, capsules and the like, which may contain at least one excipient such as starch, calcium carbonate, sucrose ), Lactose, gelatin and the like. In addition to simple excipients, lubricants such as magnesium stearate and talc are also used. Examples of the liquid preparation for oral use include suspensions, solutions, emulsions, and syrups. In addition to water and liquid paraffin, simple diluents commonly used, various excipients such as wetting agents, sweeteners, fragrances, preservatives and the like may be included . Formulations for parenteral administration include sterile aqueous solutions, non-aqueous solvents, suspensions, emulsions, freeze-dried preparations, and suppositories. Non-aqueous solvents and suspensions may include propyleneglycol, polyethylene glycol, vegetable oils such as olive oil, injectable esters such as ethyl oleate, and the like. Examples of the suppository base include witepsol, macrogol, tween 61, cacao paper, laurin, glycerogelatin and the like.

In another aspect, the present invention relates to a health functional food for alleviating or inhibiting side effects caused by olmesartan containing linaryl acetate as an active ingredient.

In the present invention, the adverse effect caused by olmesartan may be a heart rate increase or tachycardia.

In another aspect, the present invention relates to a pharmaceutical health functional food for preventing or ameliorating heart rate increase or tachycardia comprising linaryl acetate as an active ingredient.

As used herein, the term " improvement " is meant to include preventing, ameliorating, treating, or delaying the onset of such symptoms.

As used herein, the term " functional food " means food prepared and processed using raw materials or ingredients having useful functions in the human body, and " functional " ≪ / RTI > is intended to be taken for the purpose of obtaining a beneficial effect for health use such as action.

The health food of the present invention can be used as it is, or can be used together with other food or food ingredients, and can be suitably used according to conventional methods.

There is no particular limitation on the kind of the food. Examples of the food include dairy products including drinks, meat, sausages, bread, biscuits, rice cakes, chocolate, candies, snacks, confectionery, pizza, ramen noodles, other noodles, gums, ice cream, various soups, And a combination thereof, all of which include health foods in a conventional sense.

Linaryl acetate according to the present invention can be added directly to food or used with other food or food ingredients, and can be suitably used according to conventional methods. The amount of the active ingredient to be mixed can be suitably determined according to its use purpose (for prevention or improvement). Generally, the amount of linaryl acetate in the health food may be 0.01 to 15% by weight of the total food, and the health beverage composition may be added in a proportion of 0.02 to 5 g, preferably 0.3 to 1 g, based on 100 ml. However, in the case of long-term intake intended for health and hygiene purposes or for the purpose of controlling health, the amount may be less than the above range, and since there is no problem in terms of safety, the active ingredient may be used in an amount exceeding the above range.

The health functional beverage composition of the present invention is not particularly limited to the other ingredients except that the linaryl acetate is contained as an essential ingredient in the indicated ratio and may contain various flavors or natural carbohydrates as an additional ingredient such as ordinary beverages . Examples of the above-mentioned natural carbohydrates include monosaccharides such as glucose, fructose and the like; Disaccharides such as maltose, sucrose and the like; And polysaccharides such as dextrin, cyclodextrin and the like, and sugar alcohols such as xylitol, sorbitol and erythriol. As natural flavors other than those described above, natural flavors (such as tau martin, stevia extract (e.g., rebaudioside A, glycyrrhizin)) and synthetic flavors (saccharin, aspartame, etc.) have.

In addition to the above, the food of the present invention may contain various nutrients, vitamins, minerals (electrolytes), flavorings such as synthetic flavors and natural flavors, colorants, and proofing agents (cheese, chocolate, etc.). Organic acids, protective colloid thickeners, pH adjusting agents, stabilizers, preservatives, glycerin, alcohols, carbonating agents used in carbonated drinks, and the like.

In addition, the linaryl acetate of the present invention may contain flesh for the production of natural fruit juices and fruit juice drinks and vegetable drinks. These components may be used independently or in combination. The ratio of such additives is not so important, but is generally selected in the range of 0 to about 20 parts by weight based on 100 parts by weight of the linaryl acetate of the present invention.

In another aspect, the present invention provides a method of preventing or treating adverse reactions caused by olmesartan, comprising administering to a subject a pharmaceutical composition comprising linaryl acetate as an active ingredient.

In another aspect, the present invention provides a method for preventing or treating heart rate increase or tachycardia induced by olmesartan, comprising administering to a subject a pharmaceutical composition comprising linaryl acetate as an active ingredient.

In another aspect, the present invention provides the use of a pharmaceutical composition comprising linaryl acetate as an active ingredient in the prevention or treatment of adverse reactions caused by olmesartan.

In another aspect, the present invention provides the use of a pharmaceutical composition comprising linaryl acetate as an active ingredient in the prevention or treatment of olmesartan-induced heart rate increase or tachycardia.

As used herein, the term " administration " is meant to include the provision of any desired composition of the invention to a subject in any suitable manner.

In the present invention, the route of administration of the pharmaceutical composition may be, but not limited to, oral, intravenous, intramuscular, intraarterial, intramedullary, intrathecal, intracardiac, transdermal, subcutaneous, intraperitoneal, intranasal, Topical, sublingual, or rectal.

The composition of the present invention may be administered orally or parenterally, and it is preferable to select parenterally when injecting parenterally or intraperitoneally, intramuscularly, subcutaneously, intravenously, intramuscularly or intrasternally , But is not limited thereto.

The preferred dosage of the composition of the present invention varies depending on the condition and the weight of the patient, the degree of disease, the type of drug, the route of administration and the period of time, but can be appropriately selected by those skilled in the art. However, for the desired effect, the composition is preferably administered at a dose of 0.0001 to 100 mg / kg per day, preferably 0.001 to 10 mg / kg per day, but is not limited thereto. The above administration may be carried out once a day or several times. The dose is not intended to limit the scope of the invention in any way.

The composition according to the present invention has a merit that it contains biologically-friendly and excellent stability by containing natural product linaryl acetate as an active ingredient, so that it can be usefully used for the development of safe treatment of increase of heart rate and tachycardia, which are side effects of olmesartan do.

[Example]

Hereinafter, the present invention will be described in more detail with reference to Examples. It is to be understood by those skilled in the art that these embodiments are only for illustrating the present invention and that the scope of the present invention is not construed as being limited by these embodiments.

Example  1: Measurement of heart rate after completion of hypertensive rat model

To induce hypertension in rats, chronic stress and nicotine induced hypertensive rats were used. (Effects of Citrus aurantium L. var. Amara on blood pressure and blood vessel tension in hypertensive rats, Ph.D. thesis, 2017).

Male rats of 4 weeks old were randomly divided into normal and hypertensive groups. In the hypertensive group, 0.8 mg / kg of nicotine was injected intraperitoneally for 3 weeks, and 3 mg / kg of nicotine was injected intraperitoneally on the 22nd day. Normal blood pressure group took rest instead of stress and injected intraperitoneally with physiological saline of the same volume as nicotine. After 30 minutes of injection, heart rate was measured non-invasively using a rat tail (CODA HT-4, Kent Scientific Corporation, Torrington, Connecticut, USA).

As a result, it was confirmed that there was no difference in heart rate between normal blood pressure group and hypertensive group after injection of physiological saline or high concentration nicotine on the 22nd day of experiment (Fig. 1).

Example  2: Rina Lil  acetate( linalyl  acetate, LA) Olmesan ( olmesartan , OM ) Prevention or treatment effect of side effect

To evaluate the effect of linalyl acetate (LA) on the increase in heart rate, olmesartan (OM) side effect, 10 mg / kg oral olmesartan or linaryl acetate 10 mg / kg daily for 1 week after completion of hypertensive rat model, kg and 100 mg / kg, respectively. The heart rate was measured 30 minutes after the injection as in Example 1. The 36 hypertensive groups in Example 1 were randomly divided into a hypertensive control group, a olmesartan 10 mg / kg group, a linaryl acetate 10 mg / kg injection group, a linaryl acetate 100 mg / kg injection group, an olmesatin 10 mg / 5 mg / kg of acetate, 10 mg / kg of olmesartan and 100 mg / kg of linaryl acetate.

As a result, a statistically significant increase in heart rate was observed in the olmesartan 10 mg / kg group compared to the hypertension control group (p = 0.005). This increase in heart rate was not observed in the injections of linaryl acetate 10 mg / kg and linaryl acetate 100 mg / kg. In particular, a statistically significant decrease in heart rate was observed (p = 0.013) (Fig. 2) in the case of 10 mg / kg of olmesartan and 10 mg / kg of linaryl acetate compared with olmezartan 10 mg / kg alone.

From the above experimental results, it was confirmed that linaryl acetate has an excellent effect in preventing and treating an increase in heart rate, which is a side effect of olmesartan.

While the present invention has been particularly shown and described with reference to specific embodiments thereof, those skilled in the art will appreciate that such specific embodiments are merely preferred embodiments and that the scope of the present invention is not limited thereto will be. It is therefore intended that the scope of the invention be defined by the claims appended hereto and their equivalents.

Claims (6)

A pharmaceutical composition for alleviating or inhibiting side effects caused by olmesartan (OM) comprising linalyl acetate (LA) as an active ingredient.
The pharmaceutical composition according to claim 1, wherein the adverse effect caused by olmesartan is a heart rate increase or tachycardia.
A pharmaceutical composition for preventing or treating heart rate increase or tachycardia induced by olmesartan (OM) comprising linalyl acetate (LA) as an active ingredient.
A health functional food for alleviating or inhibiting side effects caused by olmesartan (OM) comprising linalyl acetate (LA) as an active ingredient.
4. The health functional food according to claim 3, wherein the adverse effect caused by olmesartan is a heart rate increase or tachycardia.
A health functional food for preventing or ameliorating heart rate increase or tachycardia induced by olmesartan (OM) comprising linalyl acetate (LA) as an active ingredient.

Images